GLP-1, Ozempic & Longevity: Evidence, Risks & Biological Age

Ozempic, Wegovy, Semaglutide. These names dominate headlines, social media feeds, and conversations in medical practices worldwide. What began as a medication for type 2 diabetes has become the symbol of a new era in weight management. Demand is so high that pharmacies in Germany, the US, and Australia have faced months-long shortages. But behind the rapid weight loss lies a medically far more complex story.

The intersection of GLP-1, Ozempic, and longevity goes far beyond the scale. These medications touch fundamental processes of metabolism, heart health, and potentially biological aging. They are not lifestyle products. They are a serious medical intervention with real side effects and far-reaching consequences for your body.

What can GLP-1 agonists really do? What are the risks? And why is comprehensive medical supervision with precise diagnostics essential? The central question is not whether you lose weight with Ozempic, but what happens in your body while you do, and what comes after.

What Are GLP-1 Agonists and How Do They Work?

GLP-1 stands for "Glucagon-like Peptide-1," a hormone your gut releases after a meal. It regulates blood sugar and appetite via four main mechanisms.

Insulin secretion: GLP-1 stimulates the pancreas to release more insulin after eating, but only when blood sugar is already elevated (glucose-dependent). This significantly lowers the risk of hypoglycemia compared to older diabetes medications.

Glucagon inhibition: It reduces the release of glucagon, which instructs the liver to release sugar, thereby stabilizing your blood sugar.

Delayed gastric emptying: Food remains in the stomach longer, prolonging the feeling of fullness.

Effects in the brain: GLP-1 acts directly on the hypothalamus, reducing hunger and cravings for high-energy foods.

Medications like semaglutide (in Ozempic and Wegovy) or liraglutide mimic this effect but are broken down much more slowly. Natural GLP-1 has a half-life of a few minutes; semaglutide lasts about a week. This results in a constant regulatory effect on appetite and blood sugar.

Clinical Evidence: Far More Than Just Weight Loss

The approval of semaglutide was originally based on its ability to control blood sugar in type 2 diabetes. Large clinical trials have since shown that its effects extend considerably further.

Cardiovascular Protection

The SELECT trial examined over 17,600 overweight or obese patients without diabetes but with existing cardiovascular disease. The results in the New England Journal of Medicine were clear: Over approximately 40 months, semaglutide reduced the risk of a major adverse cardiovascular event (heart attack, stroke, or cardiovascular death) by 20% compared to placebo (Lincoff et al., NEJM 2023).

This protective effect relies on several factors. Less body fat directly relieves the heart. GLP-1 agonists lower blood pressure. They reduce high-sensitivity C-reactive protein (hs-CRP), a systemic inflammatory marker that is also measured in the YEARS Core® program. Additionally, there is evidence of direct positive effects on blood vessel walls and a slowed progression of atherosclerosis.

Effects on Kidneys and Metabolism

The SUSTAIN-6 trial demonstrated a significant reduction in the risk of new or worsening diabetic kidney disease (Marso et al., NEJM 2016). Kidney damage is among the most common and consequential complications of diabetes and metabolic syndrome, making this effect clinically highly relevant.

On a metabolic level, therapy often improves the HOMA index, which measures insulin resistance. Improved insulin sensitivity is a crucial step in breaking the vicious cycle of metabolic syndrome.

Hype, Risks, and the Price of Success

The immense hype surrounding GLP-1 agonists often obscures the fact that these are highly potent medications with a clear risk profile.

Common Side Effects

The most common side effects affect the gastrointestinal tract, a direct consequence of delayed gastric emptying:

• Nausea (up to 44% of patients)
• Diarrhea (up to 30%)
• Vomiting
• Constipation

These symptoms are usually dose-dependent, occur primarily at the start of therapy, and frequently improve over time. For some patients, however, they still lead to discontinuation of the treatment.

Serious Risks and Contraindications

Beyond gastrointestinal discomfort, there are rarer but more severe risks:

Pancreatitis: The risk of acute inflammation of the pancreas is elevated.

Gallbladder disease: Gallstones and gallbladder inflammation occur more frequently.

Thyroid C-cell tumors: An increased risk for this rare type of cancer was observed in animal studies. The relevance for humans is unclear, but the medications are contraindicated for individuals with a family history (e.g., Multiple Endocrine Neoplasia type 2).

Ileus: There are reports of potentially life-threatening bowel obstructions due to severely slowed intestinal motility.

These risks demonstrate: GLP-1 agonists do not belong in self-medication.

Muscle Loss and the "Ozempic Body"

An underestimated problem is the composition of the lost weight. During rapid weight loss, not only fat but also muscle mass is lost. According to a meta-analysis of randomized controlled trials, up to 40% of the weight lost under semaglutide can come from lean mass (muscles and organs) (Sargeant et al., Diabetes, Obesity and Metabolism 2024).

The consequences are concrete: A lower basal metabolic rate makes it easier to regain weight after stopping the medication. Physical strength and function decline. In the worst case, "sarcopenic obesity" develops, a condition where a person has dangerously low muscle mass despite a normal weight—a state that increases cardiovascular risk and the risk of falls.

Targeted strength training and a protein-rich diet are therefore not optional additions but an integral part of any GLP-1 therapy. Continuous monitoring of body composition, such as through a 3D body scan or bioimpedance analysis, as included in the YEARS Core® program, thus becomes a critical component of therapeutic support.

GLP-1, Ozempic, and Longevity: The Impact on Biological Age

The most exciting question for preventive medicine goes beyond weight and cardiovascular risk: Can GLP-1 agonists slow the aging process? The data on GLP-1, Ozempic, and longevity is still emerging, but the mechanisms are plausible.

Inflammation and Insulin Resistance as Drivers of Aging

Chronic, low-grade inflammation ("inflammaging") and increasing insulin resistance are among the well-documented drivers of biological aging. GLP-1 agonists effectively lower inflammatory markers like hs-CRP and improve insulin sensitivity, measurable by the HOMA index. Addressing these two mechanisms directly intervenes in central aging processes.

Epigenetic Clocks

The most advanced method for assessing biological age is epigenetic clocks. They analyze methylation patterns on the DNA that change with age. In the YEARS Evolve® program, seven of these clocks are analyzed to provide an assessment of biological age and the pace of aging.

Real-world research projects are currently investigating whether metabolic improvements under semaglutide translate into slowed epigenetic aging. Clocks that correlate strongly with metabolic factors are particularly relevant here. Robust results from long-term observations are still pending.

From Treatment to Prevention

This perspective shifts the use of GLP-1 agonists: away from purely treating established diseases, toward a tool for primary prevention. For a person with high cardiovascular risk, proven insulin resistance, and elevated inflammatory markers—all measurable in the YEARS Core® screening—such therapy, embedded in a lifestyle program, could substantially lower the risk of future diseases.

Why Diagnostics Are the Deciding Factor

Individual responses to GLP-1 agonists vary considerably. Without detailed baseline diagnostics and regular monitoring, you are operating in the dark.

A comprehensive diagnostic program like YEARS Core® provides the data points to safely manage GLP-1 therapy:

Baseline assessment: What is the exact status of your insulin resistance (HOMA index)? How high is your cardiovascular risk (ApoB, hs-CRP, NT-proBNP)? What about your lung function (body plethysmography) and maximum oxygen uptake (VO₂max)? Without these starting values, an informed decision is impossible.

Monitoring success: The number on the scale alone is not enough. Are the crucial biomarkers improving? Is arterial stiffness decreasing? Is physical performance increasing? Regular measurements of these parameters allow for an objective assessment.

Identifying risks: Is your body composition changing negatively? Are there signs of liver or kidney strain? A broad laboratory panel reveals early warning signs long before symptoms appear.

Personalization: Is a lower dose sufficient? Do nutrition and training need to be adjusted to counteract muscle loss? The data answers these questions concretely.

The combination of medical intervention and precise diagnostics, as offered within the YEARS programs, represents the current standard of modern preventive medicine. The YEARS Evolve® program offers an even more detailed level of analysis with whole-body MRI and the measurement of biological clocks.

A Potent Tool, Not a Miracle Cure

GLP-1 agonists like Ozempic represent genuine medical progress. They demonstrably reduce the risk of cardiovascular disease by 20%, protect the kidneys, and fundamentally improve metabolic health. As part of a longevity strategy, they are a serious candidate.

At the same time, they require continuous use to maintain the effect, cause nausea in up to 44% of patients, and can lead to significant muscle loss if used without supervision. Uncontrolled off-label use without medical guidance is negligent.

GLP-1 therapy unfolds its preventive potential under three conditions: as part of a strategy that includes nutrition, targeted strength training, and sleep; based on a clear medical indication and risk assessment; and accompanied by diagnostics that objectively document your condition before, during, and after therapy.

Like a scalpel in trained hands, this medication can deliver precise results. In untrained hands, it causes harm.

If you want to understand what your personal metabolic and cardiovascular risk profile looks like and which strategies make sense for your long-term health, a comprehensive, data-driven analysis is the first step.

→ Schedule a consultation at YEARS

---

This article is for general informational purposes and does not replace individual medical advice. The decision for or against medical therapy must always be made in consultation with a qualified physician.

Sources

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221-2232. DOI: 10.1056/NEJMoa2307563

Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844. DOI: 10.1056/NEJMoa1607141

Neeland, I. J., Linge, J., Birkenfeld, A. L., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.15728